Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer and specific other HER2-positive malignancies, is a component of the drug Hertraz 440mg. Trastuzumab stops the growth and proliferation of cancer cells by specifically targeting the HER2 protein, which is overexpressed in HER2-positive tumours. Hertraz is frequently used as a component of chemotherapy regimens or other targeted medicines for malignancies that are HER2-positive. It is injected intravenously while being monitored by a doctor. The drug is a crucial part of targeted therapy in the treatment of breast cancer and has dramatically improved treatment outcomes for individuals with HER2-positive tumours. To successfully control any adverse effects during therapy, routine monitoring is crucial.
1. Breast cancer that is HER2-positive a kind of breast cancer in which the tumour cells overexpress the HER2 protein can be treated with Hertraz.
2. Metastatic Breast Cancer: It is used to treat HER2-positive metastatic breast cancer.
3. Hertraz is also used to treat advanced or metastatic gastric or gastroesophageal junction adenocarcinomas that are HER2-positive.
1. Reactions to the infusion: During or after the infusion, some individuals may develop reactions to the infusion, including fever, chills, nausea, and headache.
2. Trastuzumab may result in cardiac toxicity, which can impair heart function. Throughout treatment, regular heart function monitoring is crucial.
3. Weakness and fatigue are frequent adverse effects that some people experience.
4. Trastuzumab may make some patients feel queasy.
5. Some patients may develop nausea and vomiting while receiving therapy.
6. Low Blood Cell Counts: Hertraz may cause a drop in platelet, red, and white blood cell counts.
7. Rarely, it may result in respiratory issues including coughing or shortness of breath.
8. Trastuzumab may impair liver function, causing abnormally high levels of liver enzymes.
9. Hypersensitivity Reactions: Severe allergic reactions that necessitate emergency medical attention can occasionally occur in rare circumstances.
10. Trastuzumab may make infections more likely, particularly in patients getting combo therapy.
Hertraz 440mg (Mylan's Trastuzumab) should only be administered to patients under the guidance of trained medical experts who can carefully monitor its effects and successfully manage any potential side effects. The choice to administer Hertraz should be made in conjunction with the patient's individual cancer type, stage, and overall health. Throughout treatment, it is crucial to regularly check heart function, blood cell counts, and treatment response.